Attached files

file filename
EX-99.2 - PRESS RELEASE - MABVAX THERAPEUTICS HOLDINGS, INC.ex99-2.htm
EX-99.1 - PRESS RELEASE - MABVAX THERAPEUTICS HOLDINGS, INC.ex99-1.htm
 

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): October 11, 2017
 
 
MABVAX THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
 
Delaware
 
000-31265
 
93-0987903
(State or other jurisdiction of incorporation)
 
 
(Commission File Number)
 
 
(IRS Employer Identification No.)
 
 
11535 Sorrento Valley Rd., Suite 400
San Diego, CA 92121
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (858) 259-9405
 
N/A
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company [X]
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
 
 
 

 
 
 
Item 8.01
Other Events.
 
On October 11, 2017, MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”) announced that it had entered into definitive agreements with select accredited investors for the sale of 769,231 shares of the Company’s common stock for aggregate gross proceeds of $500,000. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
Also on October 11, 2017, the Company issued a press release announcing the initiation of patient enrollment at a second site for its radioimmunotherapy product. A copy of this press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
Exhibit
 
 
No.
 
Description
 
Press release announcing offering, issued October 11, 2017
99.2
 
Press release announcing initiation of patient enrollment, issued October 11, 2017
 

 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MABVAX THERAPEUTICS HOLDINGS, INC.
 
 
 
 
Dated: October 11, 2017
 
 
 
 
 
/s/ Gregory P. Hanson
 
 
 
 
 
 
Gregory P. Hanson
 
 
 
 
 
 
Chief Financial Officer